公开(公告)号：WO2023028494A2

公开(公告)日：2023-03-02

申请号：PCT/US2022/075362

申请日：2022-08-23

申请人： THE CHILDREN'S HOSPITAL OF PHILADELPHIA ,  MYRIO THERAPEUTICS PTY LTD

发明人： BEASLEY, Matthew ,  KIEFEL, Ben ,  MARIS, John ,  YARMARKOVICH, Mark ,  GRACEY, Fiona ,  SGOURAKIS, Nickolaos ,  WARRINGTON, John ,  MARSHALL, Quinlen

IPC分类号： A61K35/15 ,  A61K39/00 ,  C12Q1/6881 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K39/001102 ,  A61K39/001112 ,  A61K39/001186 ,  A61P35/00 ,  C07K14/7051 ,  C07K2319/03

摘要： The neuroblastoma immunopeptidome is enriched with peptides derived from proteins essential for tumorigenesis including the unmutated peptide QYNPIRTTF (SEQ ID NO: 1) discovered on HLA-A*24:02 which is derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B. To target QYNPIRTTF, peptide-centric chimeric antigen receptors (PC-CARs) were developed via a counter panning strategy using predicted potentially cross-reactive peptides. Informed by computational modeling, PHOX2B peptide¬ centric CARs were demonstrated to also recognize QYNPIRTTF (SEQ ID NO: 1) presented by HLA-A*23:01 and the highly divergent HLA-B*14:02. Potent and specific killing of neuroblastoma cells expressing these HEAs in vitro was shown along with complete tumor regression in mice.

公开(公告)号：WO2023009700A2

公开(公告)日：2023-02-02

申请号：PCT/US2022/038640

申请日：2022-07-28

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SHAPIRO, Gary

发明人： TAKE, Chihiro ,  KASSAI, Yoshiaki ,  HE, Xingyue ,  KUHN, Chantal

IPC分类号： C07K16/28 ,  C07K16/30 ,  C12N15/86 ,  A61K2039/5156 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/523 ,  C07K14/5443 ,  C07K14/7051 ,  C07K2317/622 ,  C07K2319/03

摘要： Disclosed herein are engineered immune cells that specifically recognizes mesothelin and expresses IL-15 and optionally CCL19. Also disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes mesothelin, and a 4- IBB intracellular region; and a polynucleotide encoding IL- 15; and optionally a polynucleotide encoding CCL19, vectors, pharmaceutical compositions comprising the nucleic acid molecules, and methods of using the engineered immune cells.

公开(公告)号：WO2022238963A2

公开(公告)日：2022-11-17

申请号：PCT/IB2022/054447

申请日：2022-05-12

申请人： CRISPR THERAPEUTICS AG

发明人： TERRETT, Jonathan Alexander ,  DEQUEANT, Mary-Lee ,  WILL, Matthias

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/828 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/892 ,  A61K35/17 ,  A61K39/001138 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2319/03 ,  C12N15/1138 ,  C12N15/625 ,  C12N2310/20 ,  C12N5/0636

摘要： A method for treating a solid tumor (e.g., a CD70+ solid tumor) comprising one or more cycles of treatment, each cycle comprising administering to a human patient in need thereof an effective amount of a population of genetically engineered T cells after a lymphodepleting therapy, and optionally a treatment comprising an anti-CD38 antibody. The population of genetically engineered T cells comprises T cells expressing a chimeric antigen receptor (CAR) that binds CD70.

公开(公告)号：WO2022234134A1

公开(公告)日：2022-11-10

申请号：PCT/EP2022/062374

申请日：2022-05-06

申请人： INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS) ,  HOSPITAL CLÍNIC DE BARCELONA ,  UNIVERSITAT DE BARCELONA

发明人： JUAN OTERO, Manel ,  URBANO ISPIZUA, Álvaro ,  PASCAL CAPDEVILA, Mariona ,  YAGÜE RIBES, Jordi ,  DELGADO GONZÁLEZ, Julio ,  ESTEVE REYNER, Jordi

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K35/17 ,  A61K2039/5156 ,  A61K39/001112 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/00 ,  C12N2510/00

摘要： The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

公开(公告)号：WO2022221726A2

公开(公告)日：2022-10-20

申请号：PCT/US2022/025115

申请日：2022-04-15

申请人： JUNO THERAPEUTICS, INC. ,  CELGENE CORPORATION

发明人： RYTLEWSKI, Julie Ann ,  PITTARI, Gianfranco

IPC分类号： A61K31/5377 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K31/573 ,  A61K39/001117 ,  C07K14/7051 ,  C07K2319/03

摘要： Provided herein are methods, compositions, and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA). In some aspects, the present disclosure relates to certain combination therapies that include administration of a cell therapy, such as a BCMA-targeted T cell therapy, in combination with immunomodulatory agents and other agents, such as dexamethasone, including for the treatment of subjects with multiple myeloma. In some embodiments, the multiple myeloma is a relapsed or refractory multiple myeloma.

公开(公告)号：WO2022216963A1

公开(公告)日：2022-10-13

申请号：PCT/US2022/023883

申请日：2022-04-07

申请人： JANSSEN BIOTECH, INC.

发明人： SUKUMAR, Madhusudhanan ,  GANESAN, Rajkumar ,  SINGH, Sanjaya ,  ORAVECZ, Tamas

IPC分类号： C07K14/725 ,  A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  A61K2039/5156 ,  A61K39/0011 ,  A61K39/001117 ,  C07K14/7051 ,  C07K2319/03 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00 ,  C12N5/0636

摘要： The present disclosure provides methods for generating stem-cell like memory T (TSCM) cells. The present disclosure also provides cells, pharmaceutical compositions, and their uses in adoptive immunotherapy for treatment of a disease, such as cancer.

公开(公告)号：WO2022174035A2

公开(公告)日：2022-08-18

申请号：PCT/US2022/016119

申请日：2022-02-11

申请人： SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE

发明人： KONING, Ryan ,  JOHNSON, Adam ,  SAXBY, Chris ,  JENSEN, Michael C. ,  BLUMENTHAL, Ian ,  REID, Aquene

IPC分类号： C07K14/435 ,  A61K38/16 ,  C07K14/705 ,  A61K35/12 ,  A61K38/17 ,  A61K2039/5156 ,  A61K39/001104 ,  A61K39/001112 ,  A61K41/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/721 ,  C07K2319/03

摘要： Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.

公开(公告)号：WO2022147444A2

公开(公告)日：2022-07-07

申请号：PCT/US2021/073145

申请日：2021-12-29

申请人： ALAUNOS THERAPEUTICS, INC.

发明人： OLIVARES, Simon ,  SINGH, Harjeet ,  COOPER, Laurence James Neil ,  HURTON, Lenka Victoria

IPC分类号： C12N15/63 ,  A61K39/00 ,  A61P35/00 ,  A61P37/06 ,  C12N15/62 ,  C12N5/10 ,  C07K14/725 ,  C07K19/00 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K2039/5156 ,  A61K39/001112 ,  A61K48/005 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/7155 ,  C07K16/00 ,  C07K2319/03

摘要： Provided herein are vectors comprising a polycistronic expression casstte comprising a polynucleotide that encodes a CD 19 specific chimeric antigen receptor, a polynucleotide that encodes a cytokine, and a polynucleotide that encodes a marker protein, wherein the polynucleotide that encodes the CD 19-specific chimeric antigen receptor and the polynucleotide that encodes the cytokine coding sequence are separated by a polynucleotide sequence that comprises an F2A element, and wherein the polynucleotide sequence that encodes the cytokine and the polynucleotide sequence that encodes the marker protein are separated by a polynucleotide sequence that comprises a T2A element.

公开(公告)号：WO2022146891A2

公开(公告)日：2022-07-07

申请号：PCT/US2021/065157

申请日：2021-12-23

申请人： SANA BIOTECHNOLOGY, INC. ,  FRY, Terry, J.

发明人： SCHREPFER, Sonja ,  WENG, Lindong

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K39/001112 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2803 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N5/0636

摘要： Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

公开(公告)号：WO2022120172A2

公开(公告)日：2022-06-09

申请号：PCT/US2021/061814

申请日：2021-12-03

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： CURTISS III, Roy ,  WANDA, Soo-Young, C. ,  WANG, Shifeng

IPC分类号： C12N15/74 ,  A61K39/00 ,  C12N1/36 ,  A61K2039/5156 ,  A61K2039/523 ,  A61K39/12 ,  A61P31/14 ,  A61P31/16 ,  C07K14/3156 ,  C12N2760/16134 ,  C12N2770/20034 ,  C12R2001/42

摘要： Described within is a new much improved host- vector systems for delivery of synthesized antigens or of DNA vaccines to a diversity of animal and human hosts to elicit immune responses, especially protective immune responses to control infection and disease induction and/or transmission by bacterial, viral, parasite and fungal infectious disease agents.